Orthofix Medical Inc Revenue per Employee (OFIX), current and historic results, rankings and more, quarterly fundamentals - CSIMarket
CSIMarket
 


Orthofix Medical Inc   (NASDAQ: OFIX)
 

Orthofix Medical Inc 's Revenue per Employee

Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales


With a revenue increase of 4.15% in the second quarter 2026, year on year to cumulative value of $833 million, Orthofix Medical Inc 's revenue per employee grew on a trailing twelve months basis to $ 519,217, this marks a new company high.
Within the Healthcare sector Employees of 175 other companies have achieved higher revenue per employee. While Orthofix Medical Inc 's total ranking has deteriorated compared to the previous quarter from 1283 to 1581. Orthofix Medical Inc has 1,605 employees.


What is Sales per Employee Ratio?







OFIX Revenue per Employee (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Revenue Change 4.15 % 1.51 % 1.61 % 4.83 % 2.42 %
Sales per Employee (TTM) $ 519,217 513,984 512,160 509,979 504,079
OFIX's Total Ranking # 1581 # 1283 # 588 # 536 # 998
Seq. Revenue Change 7.32 % -10.8 % 7.21 % 1.48 % 4.6 %


Revenue per Employee Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 33
Healthcare Sector # 176
Overall Market # 1581

Revenue per Employee Statistics
High Average Low
$ 519,217 $ 315,552 $ 244,233
(Jun 30 2026)   (Jun 30 2015)



Financial Statements
Orthofix Medical Inc 's Revenue MRQ $ 211 Millions Visit OFIX's Income Statement
Orthofix Medical Inc 's Revenues TTM $ 833 Millions Visit OFIX's aggregate revenue growth
What are OFIX's Sales? Visit OFIX's Sales by Segment


  News about Orthofix Medical Inc Revenue per employee

Orthofix Medical Inc. Appoints Massimo Calafiore as New President and CEO, Achieves Record Revenue Growth


Orthofix Medical Inc., a leading global spine and orthopedics company, has announced that Massimo Calafiore will be joining the company as its new President and Chief Executive Officer. Currently serving as the CEO of LimaCorporate S.p.A., a global orthopedics company, Calafiore is expected to assume his new role at Orthofix in early 2024, following the completion of LimaCorporate s acquisition by Enovis Corporation.
In the third quarter of 2023, Orthofix Medical Inc. saw remarkable growth, with a revenue increase of 61.2% year on year, reaching a cumulative value of $668 million, marking a new company high. Furthermore, Orthofix s revenue per employee grew on a trailing twelve months basis to $667,747.




Other Ratios
Orthofix Medical Inc 's Income per Employee
Employees in Medical Equipment & Supplies
Medical Equipment & Supplies Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
OFIX's Revenue per Employee versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for OFIX's Competitors
Revenue per Employee for OFIX's Suppliers
Revenue per Employee for OFIX's Customers

You may also want to know
OFIX's Sales Growth Rates OFIX's Pe Price to earnings ratio OFIX's Receivables Turnover Ratio OFIX's Stock Quote
OFIX's Net Income Growth Rates OFIX's Ps Price to Sales ratio OFIX's Sales per Employee OFIX's Asset Turnover Ratio
OFIX's Net Margin OFIX's Pb Price to Book ratio OFIX's Financial Strength Ratios OFIX's Dividend Payout Ratio
Date modified: 2026-09-11T09:42:01+00:00




Companies with similar Revenue per Employee for 12 months ending Jun 30 2026, within Healthcare Sector Revenue per Employee Revenue 12 months ending Jun 30 2026Number of Employees Jun 30 2026
Pacira Biosciences inc   900,077.20 $ 746.164  Million 829 
Fortress Biotech Inc   897,217.95 $ 69.983  Million 78 
Alphatec Holdings Inc   892,420.59 $ 814.780  Million 913 
Merck and Co Inc   887,586.67 $ 66,569.000  Million 75,000 
Nektar Therapeutics  866,492.06 $ 54.589  Million 63 
Carlisle Companies Incorporated  863,898.31 $ 5,097.000  Million 5,900 
Verastem Inc   858,098.04 $ 87.526  Million 102 
Emergent Biosolutions Inc   855,777.78 $ 770.200  Million 900 
Bridgebio Pharma Inc   849,903.46 $ 713.069  Million 839 
Pfizer Inc  849,280.00 $ 63,696.000  Million 75,000 
Syndax Pharmaceuticals Inc   845,651.01 $ 252.004  Million 298 
Xilio Therapeutics Inc   843,315.79 $ 64.092  Million 76 
Axsome Therapeutics Inc   839,534.05 $ 776.569  Million 925 
Ionis Pharmaceuticals Inc   834,107.70 $ 1,169.419  Million 1,402 
Vir Biotechnology Inc   826,231.61 $ 303.227  Million 367 
Immunocore Holdings Plc  822,089.69 $ 430.775  Million 524 
Prothena Corporation Public Limited Company  813,880.60 $ 54.530  Million 67 
Alkermes Plc   813,488.78 $ 1,667.652  Million 2,050 
Lifevantage Corp  811,421.52 $ 180.947  Million 223 
Sanuwave Health Inc   798,236.36 $ 43.903  Million 55 
Geron Corporation  791,864.34 $ 204.301  Million 258 
Adma Biologics Inc   789,697.06 $ 510.934  Million 647 
Vericel Corporation  769,605.53 $ 306.303  Million 398 
Cerus Corporation  768,138.89 $ 221.224  Million 288 
Septerna Inc   760,630.77 $ 98.882  Million 130 
Dyadic International Inc   760,447.40 $ 3.802  Million
Transmedics Group Inc   744,396.44 $ 668.468  Million 898 
Aveanna Healthcare Holdings Inc   743,662.86 $ 2,602.820  Million 3,500 
Veracyte Inc   721,503.31 $ 544.735  Million 755 
Xtant Medical Holdings Inc   720,185.43 $ 108.748  Million 151 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.